Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:FOMX

Menlo Therapeutics (FOMX) Stock Price, News & Analysis

Menlo Therapeutics logo

About Menlo Therapeutics Stock (NASDAQ:FOMX)

Advanced Chart

Key Stats

Today's Range
$2.99
$2.99
50-Day Range
$2.99
$2.99
52-Week Range
$1.97
$4.84
Volume
N/A
Average Volume
518,350 shs
Market Capitalization
$184.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Foamix Pharmaceuticals Ltd., a late clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations for dermatological therapy in the United States, France, Denmark, and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline that has completed third pivotal Phase III clinical trial for the treatment of moderate-to-severe acne; and FMX103, which is in Phase III clinical trial for the treatment of moderate-to-severe papulopustular rosacea. The company's product pipeline includes FCD105 and FMX109 for the treatment of moderate-to-severe acne vulgaris; and FMX110 for the treatment of papulopustular rosacea. Foamix Pharmaceuticals Ltd. has development and license agreements with Bayer HealthCare AG; LEO Pharma A/S; Mylan N.V.; and Actavis plc. The company was founded in 2003 and is headquartered in Rehovot, Israel.

Receive FOMX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Menlo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

FOMX Stock News Headlines

Warning: “DOGE Collapse” imminent
Elon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week, President Trump promised to buy a Tesla to help support Musk in the face of a boycott against his company. But according to one research group, with connections to the Pentagon and the U.S. government, Elon's preparing to strike back in a much bigger way in the days ahead.
Michael J. Fox Foundation taps Palo Alto AI firm
See More Headlines

FOMX Stock Analysis - Frequently Asked Questions

Menlo Therapeutics Inc. (NASDAQ:FOMX) released its quarterly earnings data on Monday, November, 11th. The specialty pharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by $0.07.

Based on aggregate information from My MarketBeat watchlists, some other companies that Menlo Therapeutics investors own include Sorrento Therapeutics (SRNE), Pfizer (PFE), Amarin (AMRN), Bristol-Myers Squibb (BMY), Sangamo Therapeutics (SGMO), Anavex Life Sciences (AVXL) and CRISPR Therapeutics (CRSP).

Company Calendar

Last Earnings
11/11/2019
Today
5/04/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Medicinals & Botanicals
Sub-Industry
N/A
Current Symbol
NASDAQ:FOMX
Fax
N/A
Employees
80
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-74,160,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$3.60 million
Price / Cash Flow
N/A
Book Value
$1.70 per share
Price / Book
1.76

Miscellaneous

Free Float
N/A
Market Cap
$184.12 million
Optionable
Optionable
Beta
1.66
10 Stocks Set to Soar in Spring 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:FOMX) was last updated on 5/4/2025 by MarketBeat.com Staff
From Our Partners